A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands
Top Cited Papers
- 1 January 2007
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 43 (1) , 33-36
- https://doi.org/10.1016/j.oraloncology.2005.12.026
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prevalence of KIT Expression in Human TumorsJournal of Clinical Oncology, 2004
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Adenoid cystic carcinoma: A retrospective clinical reviewInternational Journal of Cancer, 2001
- Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumoursAnnals of Medicine, 2001
- Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinomaCancer Letters, 2000
- Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinomaOral Oncology, 1997
- Management of minor salivary gland carcinomasInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Chemotherapy for adenocystic carcinomaCancer, 1980